Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Current Deferred Revenue for 5 consecutive years, with $609000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 9.34% to $609000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $609000.0 through Dec 2025, up 9.34% year-over-year, with the annual reading at $609000.0 for FY2025, 9.34% up from the prior year.
  • Current Deferred Revenue hit $609000.0 in Q4 2025 for ARS Pharmaceuticals, up from $526000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.1 million in Q4 2022 to a low of $10000.0 in Q1 2023.
  • Historically, Current Deferred Revenue has averaged $1.2 million across 5 years, with a median of $609000.0 in 2025.
  • Biggest five-year swings in Current Deferred Revenue: soared 115.31% in 2022 and later crashed 82.03% in 2024.
  • Year by year, Current Deferred Revenue stood at $1.5 million in 2021, then soared by 115.31% to $3.1 million in 2022, then decreased by 1.18% to $3.1 million in 2023, then plummeted by 82.03% to $557000.0 in 2024, then increased by 9.34% to $609000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for SPRY at $609000.0 in Q4 2025, $526000.0 in Q3 2025, and $746000.0 in Q2 2025.